Virbac group
Virbac Group, a leading player in the global animal health industry, is headquartered in France and operates extensively across Europe, North America, and Asia. Founded in 1964, the company has established itself as a trusted provider of veterinary products and services, focusing on the health and well-being of companion animals and livestock. Virbac's core offerings include vaccines, pharmaceuticals, and nutritional products, all designed to enhance animal health and productivity. What sets Virbac apart is its commitment to research and development, ensuring innovative solutions tailored to the evolving needs of veterinarians and pet owners alike. With a strong market position, Virbac has achieved notable milestones, including a robust international presence and a diverse product portfolio that reflects its dedication to quality and efficacy in animal care.
DitchCarbon Score
How does Virbac group's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Virbac group's score of 24 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Virbac group's reported carbon emissions
In 2022, Virbac Group reported total carbon emissions of approximately 23,727,000 kg CO2e, all of which fall under Scope 1 emissions. This represents a notable increase from 2021, where emissions were about 20,814,000 kg CO2e, and from 2020, which recorded approximately 21,007,000 kg CO2e. The company has not disclosed any Scope 2 or Scope 3 emissions data for these years. Despite the increase in emissions, Virbac has not set specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests that the company may be in the early stages of developing a comprehensive climate strategy. Virbac's emissions intensity, measured as greenhouse gas (GHG) emissions per unit of revenue, has shown a slight improvement, with values of 0.237 in 2022 and 0.229 in 2021, indicating a focus on aligning emissions with revenue growth. As a global player in the veterinary pharmaceutical industry, Virbac's commitment to addressing climate change will be crucial in meeting future regulatory and market expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 19,186,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 15,014,000 | - | - | - |
| Scope 3 | 6,818,000 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Virbac group is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
